創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
21/02/26 GEM-CVD08 An anti-SARS-COV-2 S1 RBD antibody COVID-19 i.v. Protein Phase-1 > 10 fold higher binding affinity and >50 fold more potent blocking potency than soluble hACE2-Fc.
Neutralize authentic SARS-COV-2 virus infection of Vero E2 cells at IC50 = 0.012 - 0.062 µg/ml.
Showed binding and blocking activity against South Africa and UK mutants.
Engineered Fc to reduce potential ADE risk.
Obtained CHO-K1 CMC clone with high expression titer.
Showed potent prophylactic and desired therapeutic efficacy in rhesus monkey disease model.
問合せ
21/02/03 GEM155 FPR2-specific ligand Atopic dermatitis/ Psoriasis, Dry eye disease, IBD (Inflammatory bowel disease), Asthma, Rheumatoid arthritis Topical, Eye drop, s.c. Peptide Phase 1 GEM155 is a small (7mer) lipidated peptide ligand for pro-resolving receptor FPR2 (N-formyl peptide receptor 2) involved in regulation of innate immune system and inhibition of ILC2 function (adaptive immune system). It also has anti-microbial effect for pathogenic bacteria through fusion with functional moiety. Efficacy is seen in animal models for the indications. CMC study is almost done. Toxicity study for topical usage and subcutaneous injection is going-on. Formulation for topical use is almost finished. 問合せ
21/01/29 GEM067 c-Kit inhibitor Diabetic macular edema & Retinopathy Oral Small molecule
Phase 2a completed -Inhibits stem cell factor-induced hyperpermeability
-Reverses retinal vascular leakage in STZ-induced diabetic rats
-Improved compliance to administration (oral) than anti-VEGF therapy (intra-vitreal injection)
-Applicable to non-responders to anti-VEGF therapy
-Repositioning of a marketed drug
問合せ
21/01/29 GEM105 Viscosupplementation Knee osteoarthritis Intra-articular Poly- saccharide
Marketing authorization Cross-linked sodium hyaluronate hydrogel with sodium hyaluronate fluid. Long-lasting and sustainable efficacy due to unique rheology of the cross-linked hydrogel. Injected only once and single injection shows comparable efficacy to a multiple-injection treatment. Obtained marketing authorization as a drug. 問合せ
21/01/13 GEM239 Activation of Treg and downregulating pro-inflammatory cytokines Psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Ankylosing spondylitis, Crohn's and colitis Oral Small molecule Human POC completed Microbiomes are important for regulating human immune systems. GEM239 is a small molecule known as a gut microbial metabolite. It downregulates pro-inflammatory cytokines, and promotes differentiation of anti-inflammatory Treg cells. Human POC study in small number of psoriasis patients has been done and significant treatment effects have been seen. FDA IND approved. Clinical trial starting in 30 patients. Formulation-science has been applied. 問合せ
21/01/06 GEM238 CSN5 inhibitor Cancer i.v. Peptide Preclinical - Identifying CDK2 binding regions within the CSN5 protein
- Specifically inhibits the binding between CSN5 and CDK2 in "small complex" that is specifically expressed in cancer cells.
- It is possible to specifically inhibit the growth of cancer cells while suppressing the effect on normal cells.
問合せ
21/01/04 GEM237 Autologous chondrocyte cell therapy for cartilage repair/regeneration Chondral and osteochondral articular lesions of the knee Arthro- scopic implan- tation Cell and scaffold Launch The autologous cartilage repair system (a device kit consisting of a bioabsorbable highly porous scaffold and an enzyme for processing removed a small amount of cartilage) is for one-step surgery. It does not require an ex vivo cell expansion process. Hyaline cartilage is regenerated and long-term effectiveness is superior to the marrow stimulation procedure.
問合せ
20/12/25 GEM236 Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor Hematological (AML, ALL, lymphoma, MM) and some solid tumors (sarcoma, kidney, melanoma. etc) Oral Small molecule Phase 1/2a -NAMPT is critical for the growth/survival of hematological cancers.
-Synthetic small molecule structurally unrelated to NAMPT substrate or known inhibitors. -will be the First-In-Class drug.
-Favorable pharmacological and toxicological profiles, showed no ophthalmic toxicity.
-May increase susceptibility to other targeted cancer drugs (BCL-2, PARP, tyrosine kinase, proteasome, and HDAC inhibitors, anti-PD-1 antibodies) and DNA-damaging chemo/radiotherapy. Synergizes with tumor-specific mutations (IDH1/2, PPM1D, DNA repair deficiency).
-Phase I study, which is near completion, demonstrated favorable toxicology profile with myeloid cells dose-limiting toxicity and signs of efficacy seen in several patients.
問合せ
20/12/25 GEM235 Mineral sunscreen powder Sunscreen Topical Natural ingredient Commecial GEM235 is an easy-to-use brush applicator, filled with an effective mineral powder with SPF 50. The 100% natural formula makes GEM235 safe to use on rash-prone skin, eczema, allergy-prone skin and sensitive skin. 問合せ
20/12/21 GEM234 Crosstalk of TGF-β signal and Wnt/β-catenin signal Liver fibrosis, Nonalcoholic steatohepatitis, Kidney fibrosis, Renal fibrosis, Liver cancer, COVID-19 Injection Small molecule Preclinical GEM234 is a novel small molecular which has suppressive effects on both hepatic stellate cell activation and kidney and liver fibrosis by suppressing TGF-β/Smad pathway via inhibition effect of Wnt/β-catenin pathway. GEM234 shows a higher suppressive effect on liver cancer stem cells than 5-FU. Wnt/β catenin inhibitors can block the infection of SARS-Cov-2, and GEM234 has potential to prevent occurrence of ARDS and cardiovascular damage in COVID-19. 問合せ